GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Inventory-to-Revenue

Lifecore Biomedical (Lifecore Biomedical) Inventory-to-Revenue : 1.75 (As of May. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Lifecore Biomedical's Average Total Inventories for the quarter that ended in May. 2023 was $44.8 Mil. Lifecore Biomedical's Revenue for the three months ended in May. 2023 was $25.5 Mil. Lifecore Biomedical's Inventory-to-Revenue for the quarter that ended in May. 2023 was 1.75.

Lifecore Biomedical's Inventory-to-Revenue for the quarter that ended in May. 2023 declined from Feb. 2023 (2.29) to Feb. 2023 (1.75)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Lifecore Biomedical's Days Inventory for the three months ended in May. 2023 was 238.81.

Inventory Turnover measures how fast the company turns over its inventory within a year. Lifecore Biomedical's Inventory Turnover for the quarter that ended in May. 2023 was 0.38.


Lifecore Biomedical Inventory-to-Revenue Historical Data

The historical data trend for Lifecore Biomedical's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Inventory-to-Revenue Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.38 0.64 0.45 0.37

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.60 1.16 1.83 2.29 1.75

Competitive Comparison of Lifecore Biomedical's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Inventory-to-Revenue falls into.



Lifecore Biomedical Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lifecore Biomedical's Inventory-to-Revenue for the fiscal year that ended in May. 2023 is calculated as

Inventory-to-Revenue (A: May. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: May. 2022 ) + Total Inventories (A: May. 2023 )) / count ) / Revenue (A: May. 2023 )
=( (36 + 40.841) / 2 ) / 103.269
=38.4205 / 103.269
=0.37

Lifecore Biomedical's Inventory-to-Revenue for the quarter that ended in May. 2023 is calculated as

Inventory-to-Revenue (Q: May. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Feb. 2023 ) + Total Inventories (Q: May. 2023 )) / count ) / Revenue (Q: May. 2023 )
=( (48.696 + 40.841) / 2 ) / 25.521
=44.7685 / 25.521
=1.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifecore Biomedical  (NAS:LFCR) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lifecore Biomedical's Days Inventory for the three months ended in May. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: May. 2023 )/Cost of Goods Sold (Q: May. 2023 )*Days in Period
=44.7685/17.106*365 / 4
=238.81

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lifecore Biomedical's Inventory Turnover for the quarter that ended in May. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: May. 2023 ) / Average Total Inventories (Q: May. 2023 )
=17.106 / 44.7685
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifecore Biomedical Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318